These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 32305868)

  • 1. Zika virus envelope nanoparticle antibodies protect mice without risk of disease enhancement.
    Shukla R; Shanmugam RK; Ramasamy V; Arora U; Batra G; Acklin JA; Krammer F; Lim JK; Swaminathan S; Khanna N
    EBioMedicine; 2020 Apr; 54():102738. PubMed ID: 32305868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dengue and Zika virus infections are enhanced by live attenuated dengue vaccine but not by recombinant DSV4 vaccine candidate in mouse models.
    Shukla R; Beesetti H; Brown JA; Ahuja R; Ramasamy V; Shanmugam RK; Poddar A; Batra G; Krammer F; Lim JK; Kale S; Lal AA; Swaminathan S; Khanna N
    EBioMedicine; 2020 Oct; 60():102991. PubMed ID: 32949997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dengue virus envelope protein domain III-elicited antibodies mediate cross-protection against Zika virus in a mouse model.
    Zhou Y; Chen D; Yang L; Zou W; Duan Z; Zhang Y; Wen J
    Virus Res; 2020 Mar; 278():197882. PubMed ID: 31981774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dengue and Zika Virus Domain III-Flagellin Fusion and Glycan-Masking E Antigen for Prime-Boost Immunization.
    Lin HH; Yang SP; Tsai MJ; Lin GC; Wu HC; Wu SC
    Theranostics; 2019; 9(16):4811-4826. PubMed ID: 31367259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Yeast-produced subunit protein vaccine elicits broadly neutralizing antibodies that protect mice against Zika virus lethal infection.
    Zhang W; Qu P; Li D; Zhang C; Liu Q; Zou G; Dupont-Rouzeyrol M; Lavillette D; Jin X; Yin F; Huang Z
    Antiviral Res; 2019 Oct; 170():104578. PubMed ID: 31394119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pichia pastoris-expressed Zika virus envelope domain III on a virus-like particle platform: design, production and immunological evaluation.
    Shanmugam RK; Ramasamy V; Shukla R; Arora U; Swaminathan S; Khanna N
    Pathog Dis; 2019 Apr; 77(3):. PubMed ID: 31093663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies.
    Poddar A; Ramasamy V; Shukla R; Rajpoot RK; Arora U; Jain SK; Swaminathan S; Khanna N
    BMC Biotechnol; 2016 Jun; 16(1):50. PubMed ID: 27301568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity.
    Lai H; Paul AM; Sun H; He J; Yang M; Bai F; Chen Q
    Vaccine; 2018 Mar; 36(14):1846-1852. PubMed ID: 29490880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zika Virus-Like Particles Bearing a Covalent Dimer of Envelope Protein Protect Mice from Lethal Challenge.
    De Lorenzo G; Tandavanitj R; Doig J; Setthapramote C; Poggianella M; Sanchez-Velazquez R; Scales HE; Edgar JM; Kohl A; Brewer J; Burrone OR; Patel AH
    J Virol; 2020 Dec; 95(1):. PubMed ID: 33028720
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Shukla R; Rajpoot RK; Arora U; Poddar A; Swaminathan S; Khanna N
    Front Microbiol; 2017; 8():2644. PubMed ID: 29367852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-reactive dengue virus-derived monoclonal antibodies to Zika virus envelope protein: Panacea or Pandora's box?
    Gunawardana SA; Shaw RH
    BMC Infect Dis; 2018 Dec; 18(1):641. PubMed ID: 30526531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor.
    Dussupt V; Sankhala RS; Gromowski GD; Donofrio G; De La Barrera RA; Larocca RA; Zaky W; Mendez-Rivera L; Choe M; Davidson E; McCracken MK; Brien JD; Abbink P; Bai H; Bryan AL; Bias CH; Berry IM; Botero N; Cook T; Doria-Rose NA; Escuer AGI; Frimpong JA; Geretz A; Hernandez M; Hollidge BS; Jian N; Kabra K; Leggat DJ; Liu J; Pinto AK; Rutvisuttinunt W; Setliff I; Tran U; Townsley S; Doranz BJ; Rolland M; McDermott AB; Georgiev IS; Thomas R; Robb ML; Eckels KH; Barranco E; Koren M; Smith DR; Jarman RG; George SL; Stephenson KE; Barouch DH; Modjarrad K; Michael NL; Joyce MG; Krebs SJ
    Nat Med; 2020 Feb; 26(2):228-235. PubMed ID: 32015557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.
    Urakami A; Ngwe Tun MM; Moi ML; Sakurai A; Ishikawa M; Kuno S; Ueno R; Morita K; Akahata W
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28956764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of Dengue/Zika Virus Pathogenicity by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in Zika Virus Infection.
    Khandia R; Munjal A; Dhama K; Karthik K; Tiwari R; Malik YS; Singh RK; Chaicumpa W
    Front Immunol; 2018; 9():597. PubMed ID: 29740424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zika Virus-Like Particle (VLP) vaccine displaying Envelope (E) protein CD loop antigen elicits protective and specific immune response in a murine model.
    Cimica V; Williams S; Adams-Fish D; McMahon C; Narayanan A; Rashid S; Stedman TT
    Biochem Biophys Res Commun; 2020 Aug; 529(3):805-811. PubMed ID: 32736711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rational Design of Zika Virus Subunit Vaccine with Enhanced Efficacy.
    Tai W; Chen J; Zhao G; Geng Q; He L; Chen Y; Zhou Y; Li F; Du L
    J Virol; 2019 Sep; 93(17):. PubMed ID: 31189716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critical neutralizing fragment of Zika virus EDIII elicits cross-neutralization and protection against divergent Zika viruses.
    Tai W; He L; Wang Y; Sun S; Zhao G; Luo C; Li P; Zhao H; Fremont DH; Li F; Jiang S; Zhou Y; Du L
    Emerg Microbes Infect; 2018 Jan; 7(1):7. PubMed ID: 29362446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Japanese encephalitis virus E protein domain III immunization mediates cross-protection against Zika virus in mice via antibodies and CD8
    Duan ZL; Zou WW; Chen D; Zhu JY; Wen JS
    Virus Res; 2024 Jul; 345():199376. PubMed ID: 38643856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Zika Virus Envelope Protein Domain III as a Target of Human Neutralizing Antibodies.
    Gallichotte EN; Young EF; Baric TJ; Yount BL; Metz SW; Begley MC; de Silva AM; Baric RS
    mBio; 2019 Sep; 10(5):. PubMed ID: 31530669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insect cell-produced recombinant protein subunit vaccines protect against Zika virus infection.
    Qu P; Zhang W; Li D; Zhang C; Liu Q; Zhang X; Wang X; Dai W; Xu Y; Leng Q; Zhong J; Jin X; Huang Z
    Antiviral Res; 2018 Jun; 154():97-103. PubMed ID: 29665376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.